Endothelin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Identifiers | |
| Symbol | EDN1 |
| Entrez | 1906 |
| HUGO | 3176 |
| OMIM | 131240 |
| RefSeq | NM_001955 |
| UniProt | P05305 |
| Other data | |
| Locus | Chr. 6 p23-p24 |
| Endothelin 2
| |
| Identifiers | |
| Symbol | EDN2 |
| Entrez | 1907 |
| HUGO | 3177 |
| OMIM | 131241 |
| RefSeq | NM_001956 |
| UniProt | P20800 |
| Other data | |
| Locus | Chr. 1 p34 |
| Identifiers | |
| Symbol | EDN3 |
| HUGO | 3178 |
| OMIM | 131242 |
| RefSeq | NM_000114 |
| UniProt | P14138 |
| Other data | |
| Locus | Chr. 20 q13.2-q13.3 |
|
WikiDoc Resources for Endothelin | |
|
Articles | |
|---|---|
|
Most recent articles on Endothelin | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Endothelin at Clinical Trials.gov Clinical Trials on Endothelin at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Endothelin
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Endothelin Discussion groups on Endothelin Patient Handouts on Endothelin Directions to Hospitals Treating Endothelin Risk calculators and risk factors for Endothelin
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Endothelin | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Endothelins are 21-amino acid vasoconstricting peptides produced primarily in the endothelium that plays a key part in vascular homeostasis. Among the strongest vasoconstrictors known, endothelins are implicated in vascular diseases of several organ systems, including the heart, general circulation and brain[1][1].
Isoforms
There are three isoforms with varying regions of expression and two key receptor types, ETA and ETB.
- ETA receptors are found in the smooth muscle tissue of blood vessels, and binding of endothelin to ETA increases vasoconstriction (contraction of the blood vessel walls) and the retention of sodium. These lead to increased blood pressure.
- ETB is primarily located on the endothelial cells that line the interior of the blood vessels. When endothelin binds to ETB receptors, this leads to increased natriuresis and diuresis (the production and elimination of urine) and the release of nitric oxide (also called "NO" or endothelium-derived relaxing factor), all mechanisms that lower the blood pressure.
- Both types of ET receptor are found in the nervous system where they may mediate neurotransmission and vascular functions.
Brain and nerves
Widely distributed in the body, receptors for endothelin are present in blood vessels and cells of the brain, choroid plexus and peripheral nerves. When applied directly to the brain of rats in picomolar quantities as an experimental model of stroke, endothelin-1 caused severe metabolic stimulation and seizures with substantial decreases in blood flow to the same brain regions, both effects mediated by calcium channels[1]. A similar strong vasoconstrictor action of endothelin-1 was demonstrated in a peripheral neuropathy model in rats[1].
Balance
In a healthy individual, a delicate balance between vasoconstriction and vasodilation is maintained by endothelin, calcitonin and other vasoconstrictors on the one hand and nitric oxide, prostacyclin and other vasodilators on the other.
Overproduction of endothelin in the lungs may cause pulmonary hypertension, which can sometimes be treated by the use of an endothelin receptor antagonist, such as bosentan or sitaxsentan. The latter drug selectively blocks endothelin A receptors, decreasing the vasoconstrictive actions and allowing for increased beneficial effects of endothelin B stimulation, such as nitric oxide production. The precise effects of endothelin B receptor activation depends on the type of cells involved.
References
External links
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
